iNtRON Biotechnology, Inc. (KOSDAQ:048530)
South Korea
· Delayed Price · Currency is KRW 3,560.00
+210.00 (6.27%)
Apr 1, 2025, 3:30 PM KST
iNtRON Biotechnology Revenue
In the year 2024, iNtRON Biotechnology had annual revenue of 6.42B KRW, down -33.05%. iNtRON Biotechnology had revenue of 1.52B in the quarter ending December 31, 2024, a decrease of -59.08%.
Revenue
6.42B
Revenue Growth
-33.05%
P/S Ratio
18.25
Revenue / Employee
84.45M
Employees
76
Market Cap
113.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.42B | -3.17B | -33.05% |
| Dec 31, 2023 | 9.59B | -4.42B | -31.57% |
| Dec 31, 2022 | 14.01B | -15.30B | -52.21% |
| Dec 31, 2021 | 29.31B | -16.13B | -35.49% |
| Dec 31, 2020 | 45.43B | 37.09B | 444.28% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |